I have spent more than 25 years in academic oncology at leading centers in the United States, including Dana Farber Cancer Institute, the University of Wisconsin, Memorial Sloan Kettering Cancer Center anf the MGH Cancer Center. I have led center-wide drug development programs at each site and become a recognized leader in both New Cancer Drug Development and Gynecologic Oncology. For the past decade, I have led more than 100 physicians in the nine services that make up the Division of Solid Tumor Oncology at MSKCC. We were responsible for the medical oncology care (all solid tumors) across the center, collaborating with our colleagues in the Department of Surgery and Radiation Oncology to provide the highest quality of cancer care and ground breaking research. I was the Vice Chair of Medicine for Experimental Therapeutics and I also led the Center's Clinical Research Program within the MSKCC Cancer Center. For 10 years, I led the Center's Investigational New Drug program. Although I have moved to the MGH and retired from clinical practice, I continue to participate in teaching and lab baded translational research.For the past several years I have been a consultant for multiple biotech companies, including a period as interim CMO for Repertoire Immune Medicines in 2022.